Plaque ControlNCT06575335
Triphala Tooth Wipes in Reduction of Streptococcus Mutans Colonies
A study testing Triphala Tooth Wipe and Chlorhexidine Tooth Wipe in people with Plaque Control, run by Dow University of Health Sciences at 1 site in Pakistan.
Trial summary
This double-blind randomized clinical trial will be conducted among differently abled institutionalized children. Sixty participants aged 6-12 years with mild intellectual disability (ID) will be enrolled in the study and divided into two treatment groups. Read more about this study
- Who is it for?
- Ages 6 to 12 years
- Conditions the study is for
- Plaque Control
- What is being tested?
- Triphala Tooth Wipe and Chlorhexidine Tooth Wipe
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 sitePakistan
- Study dates
- 30 Sep 2024to 7 Nov 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 12 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Participants with informed consent
- Children with mild intellectual disability as per American Association of Mental Deficiency (AAMD)
- Age ranging from 6 to 12 years
- One treatment group will be thirty children receiving triphala tooth wipes
- The other treatment group will be thirty children receiving chlorhexidine tooth wipes
Who cannot join
- Children who had received antibiotics within 3 months
- Participants requiring urgent dental care during the period of study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Antibacterial Efficacy of Triphala Tooth Wipes in Reduction of Streptococcus Mutans Colonies in Differently Abled Children- A Randomized Clinical Trial
This double-blind randomized clinical trial will be conducted among differently abled institutionalized children. Sixty participants aged 6-12 years with mild intellectual disability (ID) will be enrolled in the study and divided into two treatment groups. The participants will be allocated in either of the two treatment arms through Sequentially Numbered, Opaque, Sealed Envelopes (SNOSE) by the principal investigator. One group will receive triphala tooth wipes and the other will be given chlorhexidine tooth wipes, both for 7 days twice a day. Supragingival plaque sample will be collected from the buccal surface of the permanent maxillary first molar and will be subjected to microbial analysis for Streptococcus mutans (S. mutans) colonies using colony-forming units per millilitre (CFU/ml).
The tooth wipes will be prepared by the principal investigator under supervision of Pharmacognosist at Department of Pharmaceutics and Pharmacognosy, University of Karachi, Pakistan.
Read the detailed description
Preparation of Tooth Wipes:
Preparation of Triphala Tooth Wipes- The triphala decoction will be prepared by the principal investigator at Department of Pharmaceutics and Pharmacognosy, University of Karachi, Pakistan under the supervision of Pharmacognocist. The three fruits of triphala will be bought in powder form from an ayurvedic drug vendor. A mixture will be made by combining equal proportion of all these three powders in distilled water. This will then be boiled till the volume reduces to 1/8th part of the initial volume.
A sweetener will be added to the decoction followed by filtering using a white muslin cloth and then storing in a sterile amber-coloured glass bottle in a refrigerator. This will preserve its organoleptic properties and its quality for fourteen days.
The decoction obtained will be subjected to dilution to obtain concentration. This will then be used to impregnate the marketed tooth wipes fabric. The triphala tooth wipes will be cut, folded individually, and then packed using the wet wipes machine in a plain white packing by local pharmaceutical company. Each pack will contain 16 wipes.
Preparation of Chlorhexidine Tooth Wipes- The commercially available chlorhexidine mouthwash containing will be purchased from the market and will then be used to impregnate the marketed tooth wipes fabric. The chlorhexidine tooth wipes will be cut, folded individually, and then packed using the wet wipes machine in a plain white packing by local pharmaceutical company. Each pack will contain 16 wipes.
Data Collection:
Consent- Before initiation of the study, informed consent will be taken from the parent and/or guardian.
Proforma- The questionnaire will consist of their demographic details and Intelligence Quotient (IQ) score. The Streptococcus mutans count will be assessed on day 1 and day 7 of the intervention.
IQ Score- Mild ID having IQ score of 50-55 to ~70 will be part of the study. This IQ score will be provided by the institute's clinical psychologist who examines and score the patient as per American Association of Mental Deficiency (AAMD) criteria.
Microbial Analysis of the Plaque Sample- Under aseptic measures, the buccal surface of the permanent maxillary first molar will be dried with cotton swab and the supragingival plaque sample will be collected on baseline and Day 7 of the intervention prior to mealtime using sterile Gracey curette 1/2 by the principal investigator. Each of the specimen will be transferred into different sterile Eppendorf tubes having in 0.5 ml phosphate-buffered saline (PBS) to prevent cell rupture or shrinkage due to osmosis. The samples will be transported in an Ice Box. This will be cultured on the mitis salivarius agar with bacitracin in Dow Research Institute of Biotechnology and Biomedical Sciences (DRIBBS) by the microbiologist. The plates will be incubated anaerobically at 37◦C for 48 h for growth of S. mutans colonies will then be assessed at the baseline and on Day 7 of the intervention. The S. mutans count will be classified as Class 0 (none), Class 1 (<102), Class 2 (103-104) and Class 3 (10≥5) CFU/ml showing negligible, low, moderate and high caries susceptibility respectively.
- Conditions
- Plaque Control
- Being tested
- Triphala Tooth Wipe, Chlorhexidine Tooth Wipe
- Keywords
- differently abled, triphala, chlorhexidine, tooth wipes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Triphala Tooth WipeOther
The wipes will be used 1 hour after meal time, twice daily for consecutively 7 days. The sachet seal will be opened, the wipe will be taken out and rest of the sachet sealed again. The wipes will be unfolded and wrapped around index finger of right hand and all surfaces of child's teeth, gums, roof of the mouth and tongue will be cleaned.
Chlorhexidine Tooth WipeOther
Same as triphala tooth wipe
| Study group | Role | What they receive |
|---|---|---|
| Triphala Tooth Wipe | Experimental | The three fruits of triphala (Terminalia chebula, Emblica officinalis and Terminalia bellerica) will be bought in powder form from an herbal drug vendor. A mixture will be made by combining equal proportion of all these three powders in distilled water. This will then be boiled till the volume reduces to 1/8th part of the initial volume. A sweetener will be added to the decoction followed by filtering using a white muslin cloth and then storing in a sterile amber-coloured glass bottle in a refrigerator. The decoction obtained will be subjected to dilution to obtain 0.6% concentration. This will then be used to impregnate the marketed tooth wipes fabric. The triphala tooth wipes will be cut, folded individually, and then packed. Each pack will contain 16 wipes. Receives: Other: Triphala Tooth Wipe |
| Chlorhexidine Tooth Wipe | Active comparator | The commercially available mouthwash containing 0.2% chlorhexidine will be purchased from the market and will then be used to impregnate the marketed tooth wipes fabric. The chlorhexidine tooth wipes will be cut, folded individually, and then packed. Each pack will contain 16 wipes. Receives: Other: Chlorhexidine Tooth Wipe |
What is being measured
The primary outcome is the main question the study is designed to answer.
Streptococcus mutans (S. mutans) count
Colony Forming Unit per millilitre (CFU/ml) classified as Class 0 (none), Class 1 (<102), Class 2 (103-104) and Class 3 (10≥5) CFU/ml showing negligible, low, moderate and high caries susceptibility
Measured: The S. mutans count will be assessed at baseline and at day 8 of the intervention.
Secondary outcomes (1)
Plaque Index
Silness and Loe Plaque Index: The score will range from 0 to 3; 0 (excellent), 0.1-0.9 (good), 1.0-1.9 (fair), and 2.0-3.0 (poor) oral hygiene.
Measured: These counts will be assessed at baseline and at day 8 of the intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Aug 2024
- Study start30 Sep 2024
- Primary completion7 Oct 2024
- Study completion7 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (43)Papers the sponsor has linked to this study.
- Other trials for Plaque ControlStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The participants will be allocated in either of the two treatment arms through Sequentially Numbered, Opaque, Sealed Envelopes (SNOSE) by the principal investigator.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dow University of Health Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sana Masood, Dow University of Health Sciences
- Investigators
- Sana Masood, BDS, Principal investigator, Dow University of Health Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06575335
- Sponsor's protocol ID
- IRB-3384/DUHS/Approval/2024/53
- Status last verified
- Feb 2025
- First submitted
- 22 Aug 2024
- Last updated
- 17 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: As it is confidential data, the investigators won't be sharing it.
Publications
Mosaddad SA, Tahmasebi E, Yazdanian A, Rezvani MB, Seifalian A, Yazdanian M, Tebyanian H. Oral microbial biofilms: an update. Eur J Clin Microbiol Infect Dis. 2019 Nov;38(11):2005-2019. doi: 10.1007/s10096-019-03641-9. Epub 2019 Aug 1.
PubMed 31372904Lin Y, Chen J, Zhou X, Li Y. Inhibition of Streptococcus mutans biofilm formation by strategies targeting the metabolism of exopolysaccharides. Crit Rev Microbiol. 2021 Sep;47(5):667-677. doi: 10.1080/1040841X.2021.1915959. Epub 2021 May 3.
PubMed 33938347Baca P, Castillo AM, Liebana MJ, Castillo F, Martin-Platero A, Liebana J. Horizontal transmission of Streptococcus mutans in schoolchildren. Med Oral Patol Oral Cir Bucal. 2012 May 1;17(3):e495-500. doi: 10.4317/medoral.17592.
PubMed 22143733Lemos JA, Palmer SR, Zeng L, Wen ZT, Kajfasz JK, Freires IA, Abranches J, Brady LJ. The Biology of Streptococcus mutans. Microbiol Spectr. 2019 Jan;7(1):10.1128/microbiolspec.gpp3-0051-2018. doi: 10.1128/microbiolspec.GPP3-0051-2018.
PubMed 30657107Lin Y, Zhou X, Li Y. Strategies for Streptococcus mutans biofilm dispersal through extracellular polymeric substances disruption. Mol Oral Microbiol. 2022 Feb;37(1):1-8. doi: 10.1111/omi.12355. Epub 2021 Nov 22.
PubMed 34727414da Rosa SV, Moyses SJ, Theis LC, Soares RC, Moyses ST, Werneck RI, Rocha JS. Barriers in Access to Dental Services Hindering the Treatment of People with Disabilities: A Systematic Review. Int J Dent. 2020 Jul 23;2020:9074618. doi: 10.1155/2020/9074618. eCollection 2020.
PubMed 32774378Carniello V, Peterson BW, van der Mei HC, Busscher HJ. Role of adhesion forces in mechanosensitive channel gating in Staphylococcus aureus adhering to surfaces. NPJ Biofilms Microbiomes. 2020 Aug 21;6(1):31. doi: 10.1038/s41522-020-00141-z.
PubMed 32826897Deshpande MA, Baliga S, Thosar N, Rathi N, Jyothishi S, Deulkar PV, Bane SP. Evaluation of antibacterial efficacy of Triphala toothwipes on oral Streptococcus mutans count in intellectually disabled children. Spec Care Dentist. 2021 Sep;41(5):619-625. doi: 10.1111/scd.12597. Epub 2021 Apr 14.
PubMed 33852738Prakash S, Shelke AU. Role of Triphala in dentistry. J Indian Soc Periodontol. 2014 Mar;18(2):132-5. doi: 10.4103/0972-124X.131299.
PubMed 24872616Penmetsa GS, B V, Bhupathi AP, Rani P S, B V S, M V R. Comparative Evaluation of Triphala, Aloe vera, and Chlorhexidine Mouthwash on Gingivitis: A Randomized Controlled Clinical Trial. Contemp Clin Dent. 2019 Apr-Jun;10(2):333-337. doi: 10.4103/ccd.ccd_583_18.
PubMed 32308299Kaur S, Michael H, Arora S, Harkonen PL, Kumar S. The in vitro cytotoxic and apoptotic activity of Triphala--an Indian herbal drug. J Ethnopharmacol. 2005 Feb 10;97(1):15-20. doi: 10.1016/j.jep.2004.09.050. Epub 2004 Dec 25.
PubMed 15652269Biradar YS, Singh R, Sharma K, Dhalwal K, Bodhankar SL, Khandelwal KR. Evaluation of anti-diarrhoeal property and acute toxicity of Triphala Mashi, an Ayurvedic formulation. J Herb Pharmacother. 2007;7(3-4):203-12. doi: 10.1080/15228940802152869.
PubMed 18928142Phetkate P, Kummalue T, Rinthong PO, Kietinun S, Sriyakul K. Study of the safety of oral Triphala aqueous extract on healthy volunteers. J Integr Med. 2020 Jan;18(1):35-40. doi: 10.1016/j.joim.2019.10.002. Epub 2019 Oct 16.
PubMed 31680053Peterson CT, Denniston K, Chopra D. Therapeutic Uses of Triphala in Ayurvedic Medicine. J Altern Complement Med. 2017 Aug;23(8):607-614. doi: 10.1089/acm.2017.0083. Epub 2017 Jul 11.
PubMed 28696777Padiyar B, Marwah N, Gupta S, Padiyar N. Comparative Evaluation of Effects of Triphala, Garlic Extracts, and Chlorhexidine Mouthwashes on Salivary Streptococcus mutans Counts and Oral Hygiene Status. Int J Clin Pediatr Dent. 2018 Jul-Aug;11(4):299-306. doi: 10.5005/jp-journals-10005-1530. Epub 2018 Aug 1.
PubMed 30397374
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Antibacterial Efficacy of Triphala Tooth Wipes in Reduction of Streptococcus Mutans Colonies in Differently Abled Children- A Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT06575335
- Acronym / sponsor ID
- IRB-3384/DUHS/Approval/2024/53
- Conditions
- Plaque Control
- Keywords
- differently abled, triphala, chlorhexidine, tooth wipes
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Dow University of Health SciencesUniversity, hospital or other
- Study start
- 30 Sep 2024 (actual)
- Primary completion
- 7 Oct 2024 (actual)
- Study completion
- 7 Nov 2024 (actual)
- First posted
- 28 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This double-blind randomized clinical trial will be conducted among differently abled institutionalized children. Sixty participants aged 6-12 years with mild intellectual disability (ID) will be enrolled in the study and divided into two treatment groups. The participants will be allocated in either of the two treatment arms through Sequentially Numbered, Opaque, Sealed Envelopes (SNOSE) by the principal investigator. One group will receive triphala tooth wipes and the other will be given chlorhexidine tooth wipes, both for 7 days twice a day. Supragingival plaque sample will be collected from the buccal surface of the permanent maxillary first molar and will be subjected to microbial analysis for Streptococcus mutans (S. mutans) colonies using colony-forming units per millilitre (CFU/ml).
The tooth wipes will be prepared by the principal investigator under supervision of Pharmacognosist at Department of Pharmaceutics and Pharmacognosy, University of Karachi, Pakistan.
Detailed description
Preparation of Tooth Wipes:
Preparation of Triphala Tooth Wipes- The triphala decoction will be prepared by the principal investigator at Department of Pharmaceutics and Pharmacognosy, University of Karachi, Pakistan under the supervision of Pharmacognocist. The three fruits of triphala will be bought in powder form from an ayurvedic drug vendor. A mixture will be made by combining equal proportion of all these three powders in distilled water. This will then be boiled till the volume reduces to 1/8th part of the initial volume.
A sweetener will be added to the decoction followed by filtering using a white muslin cloth and then storing in a sterile amber-coloured glass bottle in a refrigerator. This will preserve its organoleptic properties and its quality for fourteen days.
The decoction obtained will be subjected to dilution to obtain concentration. This will then be used to impregnate the marketed tooth wipes fabric. The triphala tooth wipes will be cut, folded individually, and then packed using the wet wipes machine in a plain white packing by local pharmaceutical company. Each pack will contain 16 wipes.
Preparation of Chlorhexidine Tooth Wipes- The commercially available chlorhexidine mouthwash containing will be purchased from the market and will then be used to impregnate the marketed tooth wipes fabric. The chlorhexidine tooth wipes will be cut, folded individually, and then packed using the wet wipes machine in a plain white packing by local pharmaceutical company. Each pack will contain 16 wipes.
Data Collection:
Consent- Before initiation of the study, informed consent will be taken from the parent and/or guardian.
Proforma- The questionnaire will consist of their demographic details and Intelligence Quotient (IQ) score. The Streptococcus mutans count will be assessed on day 1 and day 7 of the intervention.
IQ Score- Mild ID having IQ score of 50-55 to ~70 will be part of the study. This IQ score will be provided by the institute's clinical psychologist who examines and score the patient as per American Association of Mental Deficiency (AAMD) criteria.
Microbial Analysis of the Plaque Sample- Under aseptic measures, the buccal surface of the permanent maxillary first molar will be dried with cotton swab and the supragingival plaque sample will be collected on baseline and Day 7 of the intervention prior to mealtime using sterile Gracey curette 1/2 by the principal investigator. Each of the specimen will be transferred into different sterile Eppendorf tubes having in 0.5 ml phosphate-buffered saline (PBS) to prevent cell rupture or shrinkage due to osmosis. The samples will be transported in an Ice Box. This will be cultured on the mitis salivarius agar with bacitracin in Dow Research Institute of Biotechnology and Biomedical Sciences (DRIBBS) by the microbiologist. The plates will be incubated anaerobically at 37◦C for 48 h for growth of S. mutans colonies will then be assessed at the baseline and on Day 7 of the intervention. The S. mutans count will be classified as Class 0 (none), Class 1 (<102), Class 2 (103-104) and Class 3 (10≥5) CFU/ml showing negligible, low, moderate and high caries susceptibility respectively.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- The participants will be allocated in either of the two treatment arms through Sequentially Numbered, Opaque, Sealed Envelopes (SNOSE) by the principal investigator.
| Arm | Type | Receives |
|---|---|---|
| Triphala Tooth Wipe | Experimental | Other: Triphala Tooth WipeThe three fruits of triphala (Terminalia chebula, Emblica officinalis and Terminalia bellerica) will be bought in powder form from an herbal drug vendor. A mixture will be made by combining equal proportion of all these three powders in distilled water. This will then be boiled till the volume reduces to 1/8th part of the initial volume. A sweetener will be added to the decoction followed by filtering using a white muslin cloth and then storing in a sterile amber-coloured glass bottle in a refrigerator. The decoction obtained will be subjected to dilution to obtain 0.6% concentration. This will then be used to impregnate the marketed tooth wipes fabric. The triphala tooth wipes will be cut, folded individually, and then packed. Each pack will contain 16 wipes. |
| Chlorhexidine Tooth Wipe | Active comparator | Other: Chlorhexidine Tooth WipeThe commercially available mouthwash containing 0.2% chlorhexidine will be purchased from the market and will then be used to impregnate the marketed tooth wipes fabric. The chlorhexidine tooth wipes will be cut, folded individually, and then packed. Each pack will contain 16 wipes. |
Who may qualify
- Ages
- 6 to 12 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- Participants with informed consent
- Children with mild intellectual disability as per American Association of Mental Deficiency (AAMD)
- Age ranging from 6 to 12 years
- One treatment group will be thirty children receiving triphala tooth wipes
- The other treatment group will be thirty children receiving chlorhexidine tooth wipes
Key exclusion criteria (2 listed)
- Children who had received antibiotics within 3 months
- Participants requiring urgent dental care during the period of study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Triphala Tooth WipeThe wipes will be used 1 hour after meal time, twice daily for consecutively 7 days. The sachet seal will be opened, the wipe will be taken out and rest of the sachet sealed again. The wipes will be unfolded and wrapped around index finger of right hand and all surfaces of child's teeth, gums, roof of the mouth and tongue will be cleaned. | Other | Triphala Tooth Wipe |
| Chlorhexidine Tooth WipeSame as triphala tooth wipe | Other | Chlorhexidine Tooth Wipe |
Primary outcome
Streptococcus mutans (S. mutans) count
Time frame: The S. mutans count will be assessed at baseline and at day 8 of the intervention.
Colony Forming Unit per millilitre (CFU/ml) classified as Class 0 (none), Class 1 (<102), Class 2 (103-104) and Class 3 (10≥5) CFU/ml showing negligible, low, moderate and high caries susceptibility
1 secondary outcome
Plaque Index
Time frame: These counts will be assessed at baseline and at day 8 of the intervention.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2025.
- Background: PubMed 31372904Mosaddad SA, Tahmasebi E, Yazdanian A, Rezvani MB, Seifalian A, Yazdanian M, Tebyanian H. Oral microbial biofilms: an update. Eur J Clin Microbiol Infect Dis. 2019 Nov;38(11):2005-2019. doi: 10.1007/s10096-019-03641-9. Epub 2019 Aug 1.
- Background: PubMed 33938347Lin Y, Chen J, Zhou X, Li Y. Inhibition of Streptococcus mutans biofilm formation by strategies targeting the metabolism of exopolysaccharides. Crit Rev Microbiol. 2021 Sep;47(5):667-677. doi: 10.1080/1040841X.2021.1915959. Epub 2021 May 3.
- Background: PubMed 22143733Baca P, Castillo AM, Liebana MJ, Castillo F, Martin-Platero A, Liebana J. Horizontal transmission of Streptococcus mutans in schoolchildren. Med Oral Patol Oral Cir Bucal. 2012 May 1;17(3):e495-500. doi: 10.4317/medoral.17592.
- Background: PubMed 30657107Lemos JA, Palmer SR, Zeng L, Wen ZT, Kajfasz JK, Freires IA, Abranches J, Brady LJ. The Biology of Streptococcus mutans. Microbiol Spectr. 2019 Jan;7(1):10.1128/microbiolspec.gpp3-0051-2018. doi: 10.1128/microbiolspec.GPP3-0051-2018.
- Background: PubMed 34727414Lin Y, Zhou X, Li Y. Strategies for Streptococcus mutans biofilm dispersal through extracellular polymeric substances disruption. Mol Oral Microbiol. 2022 Feb;37(1):1-8. doi: 10.1111/omi.12355. Epub 2021 Nov 22.
- Background: PubMed 32774378da Rosa SV, Moyses SJ, Theis LC, Soares RC, Moyses ST, Werneck RI, Rocha JS. Barriers in Access to Dental Services Hindering the Treatment of People with Disabilities: A Systematic Review. Int J Dent. 2020 Jul 23;2020:9074618. doi: 10.1155/2020/9074618. eCollection 2020.
- Background: PubMed 32826897Carniello V, Peterson BW, van der Mei HC, Busscher HJ. Role of adhesion forces in mechanosensitive channel gating in Staphylococcus aureus adhering to surfaces. NPJ Biofilms Microbiomes. 2020 Aug 21;6(1):31. doi: 10.1038/s41522-020-00141-z.
- Background: PubMed 33852738Deshpande MA, Baliga S, Thosar N, Rathi N, Jyothishi S, Deulkar PV, Bane SP. Evaluation of antibacterial efficacy of Triphala toothwipes on oral Streptococcus mutans count in intellectually disabled children. Spec Care Dentist. 2021 Sep;41(5):619-625. doi: 10.1111/scd.12597. Epub 2021 Apr 14.
- Background: PubMed 24872616Prakash S, Shelke AU. Role of Triphala in dentistry. J Indian Soc Periodontol. 2014 Mar;18(2):132-5. doi: 10.4103/0972-124X.131299.
- Background: PubMed 32308299Penmetsa GS, B V, Bhupathi AP, Rani P S, B V S, M V R. Comparative Evaluation of Triphala, Aloe vera, and Chlorhexidine Mouthwash on Gingivitis: A Randomized Controlled Clinical Trial. Contemp Clin Dent. 2019 Apr-Jun;10(2):333-337. doi: 10.4103/ccd.ccd_583_18.
- Background: PubMed 15652269Kaur S, Michael H, Arora S, Harkonen PL, Kumar S. The in vitro cytotoxic and apoptotic activity of Triphala--an Indian herbal drug. J Ethnopharmacol. 2005 Feb 10;97(1):15-20. doi: 10.1016/j.jep.2004.09.050. Epub 2004 Dec 25.
- Background: PubMed 18928142Biradar YS, Singh R, Sharma K, Dhalwal K, Bodhankar SL, Khandelwal KR. Evaluation of anti-diarrhoeal property and acute toxicity of Triphala Mashi, an Ayurvedic formulation. J Herb Pharmacother. 2007;7(3-4):203-12. doi: 10.1080/15228940802152869.
- Individual participant dataSharing planned: No. As it is confidential data, the investigators won't be sharing it.
Related trials for Plaque Control
Active, not recruitingPhase 2
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Plaque Psoriasis
RecruitingPhase 1/2
A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
RecruitingPhase 2
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
Atherosclerosis, Coronary Artery Disease
RecruitingPhase 3
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
Atherosclerosis, Cardiovascular Diseases
Active, not recruitingPhase 3
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sana Masood, BDS principal investigator
Dow University of Health Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Triphala Tooth Wipe and Chlorhexidine Tooth Wipe in people with Plaque Control, run by Dow University of Health Sciences at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Streptococcus mutans (S. mutans) count (time frame: The S. mutans count will be assessed at baseline and at day 8 of the intervention.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06575335, which also lists 43 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2025.